34.06 0.00 (0.00%)
After hours: 4:51PM EST
|Bid||33.25 x 1000|
|Ask||34.57 x 800|
|Day's Range||33.84 - 35.55|
|52 Week Range||22.69 - 39.10|
|Beta (5Y Monthly)||0.92|
|PE Ratio (TTM)||135.70|
|Earnings Date||Feb 25, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.82|
Horizon Therapeutics plc (Nasdaq: NZNP) today announced that it has been recognized as one of the 2020 Best Workplaces in Ireland, ranking 13th in the small company category. This is the first year that Horizon has been named to the Ireland list.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its fourth-quarter and full-year 2019 financial results and provided its full-year 2020 net sales and adjusted EBITDA guidance.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March:
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis. This new dosage form provides another option for people living with cystinosis, in addition to the currently available PROCYSBI capsules.
Horizon Therapeutics plc (Nasdaq: HZNP) and Uplifting Athletes today announced a new partnership for the 2020 Reps for Rare Disease campaign, which offers an opportunity for NFL Draft prospects to give back and support the rare disease community. Participants who team up with Uplifting Athletes will dedicate their performance in one event – bench press, vertical jump or broad jump – at the NFL Scouting Combine or their school’s official pro day, to raising funds for rare disease research and awareness initiatives.
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.
Pharmaceutical stocks dipped a single-digit percentage in January, leading their biotech brethren. Still, there are standout companies among the industry group.
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter, which is partially offset by lower royalties from Relvar/Breo Ellipta.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has agreed to purchase the three-building campus in Deerfield that formerly belonged to Takeda Pharmaceuticals. The transaction is expected to close in the first quarter with additional terms of the purchase not disclosed. Horizon is expected to occupy the campus in the second half of this year.
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and external search; Srini Ramanathan, Ph.D., group vice president, development sciences and San Francisco site head and Melanie Gloria, senior vice president, R&D operations, will report to Timothy Walbert, chairman, president and chief executive officer.
The New England Journal of Medicine published Phase 3 trial data for Horizon Therapeutics’ TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease.
Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
Horizon Therapeutics today announced that the FDA has approved TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
Today we will run through one way of estimating the intrinsic value of Horizon Therapeutics Public Limited Company...
Jeffrey Hirsch -- editor of Stock Trader's Almanac -- select Global Brass and Copper Holdings as his favorite small cap stock for 2019. Following an April merger announcement, Global Brass shareholders received $44 per share in cash for a gain of roughly 75%. This year, Hirsch offers two risk-oriented ideas.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it is increasing the peak U.S. annual net sales expectations for its key growth drivers KRYSTEXXA and teprotumumab, as well as providing several pipeline updates.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® (pegloticase injection) provided an increased durability of response for people living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.